Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis

BACKGROUND: The combination therapy of trans-arterial chemoembolization (TACE) and sorafenib were proved to be one of the effective methods for intermediate and advanced hepatocellular carcinoma (HCC). Although it has been confirmed that the combination therapy can prolong survival for advanced HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yanmei, Jiang, Huijie, Jiang, Hao, Zhao, Sheng, Zeng, Xu, Sun, Ran, Zheng, Ruoshui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515486/
https://www.ncbi.nlm.nih.gov/pubmed/34628285
http://dx.doi.org/10.1016/j.tranon.2021.101238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515486/
https://www.ncbi.nlm.nih.gov/pubmed/34628285
http://dx.doi.org/10.1016/j.tranon.2021.101238

Ejemplares similares